Immunomedics Inc. ( IMMU ) was a big mover last session with its shares rising over 8% on the day. The upside was owing to the company's announcement of favorable interim phase 2 results for sacituzumab govitecan, the company's lead investigational antibody-drug conjugate (ADC) in patients with metastatic lung cancer. This development led to far more shares changing hands yesterday than in a normal session. The move continues the recent uptrend of the company as the stock has gained roughly 27% in the past one-month time frame.
This clinical-stage biopharmaceutical company has seen a mixed track record when it comes to estimate revisions of 1 increase and 1 decrease in the last 30 days. Meanwhile, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday's price action can turn into more strength down the road.
Immunomedics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the bio-med/gene industry is Gilead Sciences Inc. ( GILD ) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.